Search research articles
Contact Us
Filters
Showing results (841-850 of 855) with videos related to
Page
of 86
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society
|
November 29, 2025
Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK)
Olivier Rascol, Fabienne Ory-Magne, Wassilios G Meissner, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
April 5, 2024
Amantadine use in the French prospective NS-Park cohort
Margherita Fabbri, Vanessa Rousseau, Jean-Christophe Corvol, et al.
Nature Genetics
|
February 13, 1999
An encyclopedia of mouse genes
M Marra, L Hillier, T Kucaba, et al.
Molecular Genetics and Metabolism
|
September 3, 2017
Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies
Laura A Adang, Omar Sherbini, Laura Ball, et al.
European Heart Journal
|
February 27, 2026
Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy
Koen H M Prange, Gemma Bel-Bordes, Marie A C Depuydt, et al.
Hematological Oncology
|
February 19, 2020
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial
Christine Schmitz, Jan Rekowski, Stefan P Müller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2018
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial
Ulrich Dührsen, Stefan Müller, Bernd Hertenstein, et al.
Haematologica
|
April 16, 2026
Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study
Marie José Kersten, Martin Dreyling, Kim M Linton, et al.
Annals of Hematology
|
January 6, 2019
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial
Andreas Hüttmann, Jan Rekowski, Stefan P Müller, et al.
JAMA Pediatrics
|
March 3, 2025
ATP1A3 Variants, Variably Penetrant Short QT Intervals, and Lethal Ventricular Arrhythmias
Mary E Moya-Mendez, Minu-Tshyeto Bidzimou, Padmapriya Muralidharan, et al.
Page
of 86
Search research articles
Search
Showing results (841-850 of 855) with videos related to
Sort By:
Page
of 86
Movement Disorders : Official Journal of the Movement Disorder Society
|
November 29, 2025
Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK)
Olivier Rascol, Fabienne Ory-Magne, Wassilios G Meissner, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
April 5, 2024
Amantadine use in the French prospective NS-Park cohort
Margherita Fabbri, Vanessa Rousseau, Jean-Christophe Corvol, et al.
Nature Genetics
|
February 13, 1999
An encyclopedia of mouse genes
M Marra, L Hillier, T Kucaba, et al.
Molecular Genetics and Metabolism
|
September 3, 2017
Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies
Laura A Adang, Omar Sherbini, Laura Ball, et al.
European Heart Journal
|
February 27, 2026
Carotid plaque macrophage burden and inflammatory lipid-associated macrophage markers predict secondary major adverse cardiovascular events after endarterectomy
Koen H M Prange, Gemma Bel-Bordes, Marie A C Depuydt, et al.
Hematological Oncology
|
February 19, 2020
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial
Christine Schmitz, Jan Rekowski, Stefan P Müller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2018
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial
Ulrich Dührsen, Stefan Müller, Bernd Hertenstein, et al.
Haematologica
|
April 16, 2026
Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study
Marie José Kersten, Martin Dreyling, Kim M Linton, et al.
Annals of Hematology
|
January 6, 2019
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial
Andreas Hüttmann, Jan Rekowski, Stefan P Müller, et al.
JAMA Pediatrics
|
March 3, 2025
ATP1A3 Variants, Variably Penetrant Short QT Intervals, and Lethal Ventricular Arrhythmias
Mary E Moya-Mendez, Minu-Tshyeto Bidzimou, Padmapriya Muralidharan, et al.
Page
of 86